Pyrolysis of UR-144, a synthetic cannabinoid, augments an affinity to human CB1 receptor and cannabimimetic effects in mice

被引:18
|
作者
Kaizaki-Mitsumoto, Asuka [1 ]
Hataoka, Kyoko [1 ]
Funada, Masahiko [2 ]
Odanaka, Yuki [3 ]
Kumamoto, Hiroki [4 ]
Numazawa, Satoshi [1 ]
机构
[1] Showa Univ, Sch Pharm, Div Toxicol,Dept Pharmacol Toxicol & Therapeut, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan
[2] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, 4-1-1 Ogawa Higashi, Kodaira, Tokyo 1878553, Japan
[3] Showa Univ, Sch Pharm, Ctr Instrumental Anal, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan
[4] Showa Univ, Sch Pharm, Dept Med & Ind Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan
来源
JOURNAL OF TOXICOLOGICAL SCIENCES | 2017年 / 42卷 / 03期
关键词
UR-144; Synthetic cannabinoid; Smoking; degradant; CB1; receptor;
D O I
10.2131/jts.42.335
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Drug abusers most often smoke 'herbal incense' as a cigarette or inhale it using a smoking tool. Smoking may cause pyrolysis of the drug and produce decomposed products of which biological effect has never been investigated. The synthetic cannabinoid UR-144 is known to undergo thermal degradation, giving a ring-opened isomer, so-called UR-144 degradant. The present study demonstrates by using UR-144 as a model drug that the smoke of burned UR-144 contains the UR-144 degradant. The UR-144 degradant showed approximately four fold higher agonist activity to human CB, receptor and augmented hypothermic and akinetic actions in mice compared to UR-144. These results indicate that smoking behavior may increase psychological actions of the certain synthetic cannabinoids.
引用
收藏
页码:335 / 341
页数:7
相关论文
共 50 条
  • [21] Cannabinoid CB1 receptor mediates glucocorticoid effects on hormone secretion induced by volume and osmotic changes
    Ruginsk, S. G.
    Uchoa, E. T.
    Elias, L. L. K.
    Antunes-Rodrigues, J.
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2012, 39 (02) : 151 - 154
  • [22] Cannabinoid CB1 Receptors Are Expressed in a Subset of Dopamine Neurons and Underlie Cannabinoid-Induced Aversion, Hypoactivity, and Anxiolytic Effects in Mice
    Han, Xiao
    Liang, Ying
    Hempel, Briana
    Jordan, Chloe J.
    Shen, Hui
    Bi, Guo-Hua
    Li, Jin
    Xi, Zheng-Xiong
    JOURNAL OF NEUROSCIENCE, 2023, 43 (03): : 373 - 385
  • [23] Kinetics of human cannabinoid 1 (CB1) receptor antagonists: Structure-kinetics relationships (SKR) and implications for insurmountable antagonism
    Xia, Lizi
    de Vries, Henk
    Yang, Xue
    Lenselink, Eelke B.
    Kyrizaki, Athina
    Barth, Francis
    Louvel, Julien
    Dreyer, Matthias K.
    van der Es, Daan
    Derman, Adriaan P.
    Heitman, Laura H.
    BIOCHEMICAL PHARMACOLOGY, 2018, 151 : 166 - 179
  • [24] Functional Autoradiography Shows Unaltered Cannabinoid CB1 Receptor Signalling in Hippocampus and Cortex of APP/PS1 Transgenic Mice
    Karkkainen, E.
    Tanila, H.
    Laitinen, J. T.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2012, 11 (08) : 1038 - 1044
  • [25] Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice
    Irwin, Nigel
    Hunter, Kerry
    Frizzell, Nonna
    Flatt, Peter R.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 581 (1-2) : 226 - 233
  • [26] Age-dependent Alteration in Mitochondrial Dynamics and Autophagy in Hippocampal Neuron of Cannabinoid CB1 Receptor-deficient Mice
    Kataoka, Kosuke
    Bilkei-Gorzo, Andras
    Nozaki, Chihiro
    Togo, Akinobu
    Nakamura, Keiichiro
    Ohta, Keisuke
    Zimmer, Andreas
    Asahi, Toru
    BRAIN RESEARCH BULLETIN, 2020, 160 : 40 - 49
  • [27] Modulation of anxiety by acute blockade and genetic deletion of the CB1 cannabinoid receptor in mice together with biogenic amine changes in the forebrain
    Thiemann, Gunnar
    Watt, Carly A.
    Ledent, Catherine
    Molleman, Areles
    Hasenoehrl, Ruediger U.
    BEHAVIOURAL BRAIN RESEARCH, 2009, 200 (01) : 60 - 67
  • [28] Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation
    Mulpuri, Yatendra
    Marty, Vincent N.
    Munier, Joseph J.
    Mackie, Ken
    Schmidt, Brian L.
    Seltzman, Herbert H.
    Spigelman, Igor
    NEUROPHARMACOLOGY, 2018, 139 : 85 - 97
  • [29] Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB1/CB2 versus GPR55 receptors
    Wang, Xiao-Fei
    Galaj, Ewa
    Bi, Guo-Hua
    Zhang, Cindy
    He, Yi
    Zhan, Jia
    Bauman, Michael H.
    Gardner, Eliot L.
    Xi, Zheng-Xiong
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (08) : 1865 - 1880
  • [30] Novel selective cannabinoid CB1 receptor antagonist MJ08 with potent in vivo bioactivity and inverse agonistic effects
    Chen, Wei
    Xu, Cheng
    Liu, Hong-ying
    Long, Long
    Zhang, Wei
    Zheng, Zhi-bing
    Xie, Yun-de
    Wang, Li-li
    Li, Song
    ACTA PHARMACOLOGICA SINICA, 2011, 32 (09) : 1148 - 1158